Please select the eligibility criteria that correspond to the clinical trial below.
Title: Acclimatization Mechanisms During Ascent to 7500m. Effects of Ascent Protocol on Acute Mountain Sickness and Cardiorespiratory Physiology
Brief Summary: The trial evaluates the role of ascent protocol on acute mountain sickness and cardio-respiratory physiology during an ascent to Muztagh Ata (7546m). Two groups of mountaineers ascend with different acclimatization time to the summit. The prevalence and severity of symptoms of acute mountain sickness are evaluated along with physiologic variables.


Options:
A: Inclusion Criteria:

* Permanent residence at low (\<500 m) altitude
* Conventional systolic BP (average of two measurements) 140-159 mmHg or conventional diastolic BP 90-99 mmHg in subjects untreated or after 4 weeks of washout
* Mean daytime systolic BP ≥135 and \<150 mmHg and/or mean daytime diastolic BP ≥85 and \<95 mmHg in subjects untreated or after 4 weeks of washout
* Written informed consent to participate in the study

Exclusion Criteria:

* Conventional systolic BP (average of two measurements) ≥150 mmHg and conventional diastolic BP ≥95 mmHg in treated subjects
* Regular use of two or more antihypertensive drugs (with the exception of subjects on two antihypertensive drugs in low doses)
* Treated antihypertensive subjects in whom withdrawal of treatment is deemed unethical by the investigator (e.g. because of the existence of compelling indications other than hypertension for continuous use of previously used antihypertensive agent)
* Contraindications (including a history of adverse reactions) to angiotensin receptor blockers or calcium antagonists
* History of serious mountain sickness
* Subjects who over 3 months preceding inclusion in the study spent considerable (\> 1 week) amount of time at altitudes above 2500 m.
* Cardiovascular diseases other than hypertension (coronary heart disease, heart failure, atrial fibrillation, valvular or congenital heart disease, cardiomyopathies, cerebrovascular disease, peripheral artery disease, aortic aneurysm)
* Suspected or confirmed secondary hypertension
* Diabetes mellitus
* Serious respiratory disorders
* Other conditions deemed relevant by the investigator (including liver disease, renal disease, thyroid disorders)
* BMI ≥35 kg/m2
* Upper arm circumference \>32 cm
* known severe obstructive sleep apnea (apnea-hypopnea index \> 30 or use of CPAP) or excessive daytime sleepiness (Epworth Sleepiness Scale \> 10)
* Pregnancy
* Premenopausal women not using effective contraceptive methods
* Elevated probability of noncompliance with the study procedures
B: Inclusion Criteria:

* Healthy, physically fit subject
* Mountaineering experience

Exclusion Criteria:

* Any type of cardiac or respiratory disease
* Regular intake of any medication
* History of high altitude pulmonary oedema
* Severe acute mountain sickness at altitudes below 3500m or high altitude cerebral oedema.
C: Inclusion Criteria:

* Participant in Apex 2 high altitude expedition

Exclusion Criteria:

* Previous history of high altitude pulmonary edema
D: Inclusion Criteria:

* At least one previous episode of high altitude pulmonary edema

Exclusion Criteria:

* pulmonary arterial hypertension
* congenital heart disease
* any chronic lung disease

Answer: B